For example, Moore et al. demonstrated a statistically significant improvement of survival using the association between gemcitabine plus erlotinib, a human epidermal growth factor receptor type 1 (HER1/EGFR) inhibitor, in unresectable, locally advanced, or metastatic pancreatic cancers that often overexpress HER1/EGFR [18]. This evidence concerns the gene EGFR and pancreatic neoplasm.